|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical assays demonstrated that NICD1 and β-catenin exhibited a similar localization pattern in colon cancer tissues.
|
28947978 |
2017 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, our study reveals that miR-17-92 cluster is directly regulated by APC/β-catenin pathway and could be a potential therapeutic target in colon cancers with aberrant APC/β-catenin signaling.
|
26804172 |
2016 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
An aberrant accumulation of β-catenin in intestinal epithelial cells is relevant to the development and progression of colon cancer and is thus a potential target for the development of therapeutics for this malignancy.
|
27120392 |
2016 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
The absence of miR-21 resulted in the reduced expression of Ki67 and the attenuated proliferation of tumour cells with a simultaneous increase in E-cadherin and decrease in β-catenin and SOX9 in the tumours of CAC mice.
|
25994220 |
2016 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
An in vivo study showed that the oral administration of K-756 inhibited the Wnt/β-catenin pathway in colon cancer xenografts in mice.
|
27196752 |
2016 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Positive regulation of β-catenin-PROX1 signaling axis by DBC1 in colon cancer progression.
|
26477307 |
2016 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The current study investigates the role of tolfenamic acid on β-catenin expression in colon cancer.
|
27089389 |
2016 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Examination of colon cancer tissues from patients revealed a correlation between elevated expression levels of USP4 and β-catenin.
|
26189775 |
2015 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study suggests that oncogenic alterations activating the MAPK and Wnt/β-catenin pathways must be consecutively and coordinately selected to assure stem cell maintenance during colon cancer initiation and progression.
|
25109331 |
2015 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Taken together, our results strongly support these chalcones as novel negative modulators of the Wnt/β-catenin pathway and colon cancer cell growth in vitro.
|
25775405 |
2015 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed to investigate the roles of the CXCR4/CXCL12 axis in activation of the Wnt/β-catenin pathway in the development of colon cancers.
|
25960214 |
2015 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
DACT2 is a functional tumor suppressor through inhibiting Wnt/β-catenin pathway and associated with poor survival in colon cancer.
|
25023701 |
2015 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Microsatellite instability test and immunohistochemical examination of β-catenin and MLH1 proteins of these tumors showed that WNT signaling or microsatellite instability was less likely to be involved in the present tumors as observed in conventional left-sided or right-sided colon cancers, respectively.
|
26191323 |
2015 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
VM-positive colon cancer samples showed increased Wnt3a expression (p < 0.001) and β-catenin nuclear expression (p < 0.001) compared with the VM-negative samples.
|
26266404 |
2015 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
High CSN6 expression was positively correlated with ERK2 activation and β-catenin overexpression in CRC samples, and inhibiting CSN6 stability with cetuximab reduced colon cancer growth.
|
26267535 |
2015 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mutations in APC or CTNNB1 are highly frequent in colon cancer and cause aberrant stabilization of CTNNB1, which activates the transcription of Wnt target genes by binding to chromatin via the TCF/LEF transcription factors.
|
24651522 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Protein tyrosine phosphatase receptor U (PTPRU) has been shown to be a tumor suppressor in colon cancer by dephosphorylating β-catenin and reducing the activation of β-catenin signaling.
|
25337216 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that the down-regulation of β-catenin by genistein may constitute an important determinant of the suppression of HT-29 cell growth and may be exploited for the prevention and treatment of colon cancer.
|
24390805 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
WNT signaling and distant metastasis in colon cancer through transcriptional activity of nuclear β-Catenin depend on active PI3K signaling.
|
24930890 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Herein, we determined that inhibition of colon cancer progression is dictated by quantitatively controlling expression of the miR-17~92 cluster. miR-19 in the context of the miR-17~92 cluster at medium levels promoted tumor metastasis through induction of Wnt/β-catenin-mediated epithelial-mesenchymal transition by targeting to the tumor-suppressor gene, PTEN.
|
24681249 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated germline polymorphisms in a comprehensive panel of Wnt/β-catenin pathway genes to predict time to tumor recurrence (TTR) in patients with stage III and high-risk stage II CC.
|
23817222 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our data reveal SPRY2 as a novel Wnt/β-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.
|
23624922 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In-vitro investigation of the PKD1-β-catenin interaction in colon cancer cells reveal that PKD1 overexpression suppresses cell proliferation and clonogenic potential and enhances cell-cell aggregation.
|
25149539 |
2014 |
|
Malignant tumor of colon
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of β-catenin was elevated in T cells, including Tregs, of patients with colon cancer.
|
24574339 |
2014 |
|
Malignant tumor of colon
|
0.400 |
Biomarker
|
disease |
BEFREE |
In light of these observations, we investigated the association of T-Antigen and nuclear β-catenin in colon cancer cases and the effects of this complex in the activation of the transcription and cell cycle regulators c-Myc and Cyclin D1 in vitro.
|
25229241 |
2014 |